News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Agilent Technologies Inc.'s Chris Van Ingen to Retire at End of Fiscal Year
August 24, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE:A) today announced that Chris van Ingen, president of the company’s Bio-Analytical Measurement business, will retire on Oct. 31, 2007, the last day of Agilent’s fiscal year.
Twitter
LinkedIn
Facebook
Email
Print
People
MORE ON THIS TOPIC
Earnings
Sanofi targets late-phase and commercial M&A to offset looming Dupixent decline
October 30, 2026
·
2 min read
·
Nick Paul Taylor
Earnings
‘We need to do better,’ Alnylam CEO admits, as uncertainty looms over transthyretin franchise
October 30, 2026
·
3 min read
·
Annalee Armstrong
Venture capital
New biotech Setara forms with $90M to take on Jazz’s bonus rare disease programs
October 30, 2026
·
1 min read
·
Annalee Armstrong
Drug Development
Dren Bio lands $350M to push rare blood cancer therapy toward market
October 29, 2026
·
2 min read
·
Gabrielle Masson
